MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced that it has signed an agreement to acquire the assets of the LifeStent® product family from Edwards Lifesciences Corporation, headquartered in Irvine, California. The transaction includes cash payments of approximately $74 million upon closing and up to an additional $65 million on the achievement of certain milestones including regulatory approvals. Bard’s Peripheral Vascular division, located in Tempe, Arizona, will assume marketing responsibility for the product. The company expects to close the transaction following the satisfaction of customary conditions, including Hart-Scott-Rodino clearance.
